Mon, September 9, 2019
Fri, September 6, 2019
Thu, September 5, 2019

Matthew Harrison Maintained (VRTX) at Buy with Increased Target to $240 on, Sep 6th, 2019

Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $215 to $240 on, Sep 6th, 2019.

Matthew has made no other calls on VRTX in the last 4 months.



There are 4 other peers that have a rating on VRTX. Out of the 4 peers that are also analyzing VRTX, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Alan Carr of "Needham" Downgraded from Strong Buy to Hold on, Thursday, August 1st, 2019


These are the ratings of the 3 analyists that currently disagree with Matthew


  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $230 on, Thursday, August 1st, 2019
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $213 on, Thursday, August 1st, 2019
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $211 on, Thursday, August 1st, 2019